ATE179615T1 - Oxypurin-nukleoside und seine artverwandten, und acylderivate davon, zur verbesserung der hämatopoese - Google Patents

Oxypurin-nukleoside und seine artverwandten, und acylderivate davon, zur verbesserung der hämatopoese

Info

Publication number
ATE179615T1
ATE179615T1 AT92906893T AT92906893T ATE179615T1 AT E179615 T1 ATE179615 T1 AT E179615T1 AT 92906893 T AT92906893 T AT 92906893T AT 92906893 T AT92906893 T AT 92906893T AT E179615 T1 ATE179615 T1 AT E179615T1
Authority
AT
Austria
Prior art keywords
acyl derivatives
hematopoasis
relatives
improving
oxypurine nucleosides
Prior art date
Application number
AT92906893T
Other languages
English (en)
Inventor
Borstel Reid Warren Von
Michael Kevin Bamat
Bradley Mark Hiltbrand
James Charles Butler
Original Assignee
Pro Neuron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Neuron Inc filed Critical Pro Neuron Inc
Application granted granted Critical
Publication of ATE179615T1 publication Critical patent/ATE179615T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT92906893T 1991-02-08 1992-02-05 Oxypurin-nukleoside und seine artverwandten, und acylderivate davon, zur verbesserung der hämatopoese ATE179615T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65388291A 1991-02-08 1991-02-08

Publications (1)

Publication Number Publication Date
ATE179615T1 true ATE179615T1 (de) 1999-05-15

Family

ID=24622651

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92906893T ATE179615T1 (de) 1991-02-08 1992-02-05 Oxypurin-nukleoside und seine artverwandten, und acylderivate davon, zur verbesserung der hämatopoese

Country Status (11)

Country Link
EP (1) EP0570519B1 (de)
JP (6) JP3393645B2 (de)
KR (2) KR100263943B1 (de)
AT (1) ATE179615T1 (de)
AU (1) AU663309C (de)
CA (2) CA2444071C (de)
DE (1) DE69229108T2 (de)
IL (1) IL100874A (de)
RU (1) RU2158269C2 (de)
WO (1) WO1992013561A1 (de)
ZA (1) ZA92914B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9800452D0 (sv) * 1998-02-13 1998-02-13 Medivir Ab Antivirals
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US7307166B1 (en) 1987-10-28 2007-12-11 Wellstat Therapeutics Corporation Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis
ATE205850T1 (de) * 1991-07-05 2001-10-15 Pro Neuron Inc Behandlung der toxischen wirkung von chemotherapeutischen und antiviralen wirkstoffen mit acylierten pyrimidinnukleosiden
US5641758A (en) * 1993-11-10 1997-06-24 Kluge; Michael Cytarabine derivatives, the preparation and use thereof
US5762922A (en) * 1994-01-31 1998-06-09 Ludwig Institute For Cancer Research Antioxidants and intracellular gluthathione raising agents for therapeutic treatments
FI970588A7 (fi) * 1994-08-12 1997-04-11 Wellstat Therapeutics Corp Menetelmät verenmyrkytyksen tai tulehdussairauksien hoitamiseksi oksipuriininukleosideillä
DE69829784T2 (de) * 1997-08-15 2006-02-16 Medivir Ab 3'-Fluorierte Guanosinderivate zur Behandlung oder Prophylaxe von HBV- oder retroviralen Infektionen
WO1999051613A1 (en) * 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
KR20050085115A (ko) * 2002-11-22 2005-08-29 스미스클라인 비참 코포레이션 신규 화합물
JP3929949B2 (ja) 2003-08-08 2007-06-13 独立行政法人科学技術振興機構 酸化により機能性ユニットを放出するヌクレオシドおよびそれを含むオリゴヌクレオチドの製造法
CA2695950C (en) * 2007-08-16 2016-06-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compositions containing nucleosides and manganese and their uses
AU2016222458B2 (en) * 2007-08-16 2018-11-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions containing Nucleosides and Manganese and their Uses
CA2797716C (en) 2010-04-29 2018-09-11 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compositions containing purine and pyrimidine nucleosides, peptides, and manganese and their uses
KR20150143587A (ko) 2013-04-08 2015-12-23 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 텔로머라제 매개된 텔로미어를 변형시키기 위한 메르캅토푸린 리보뉴클레오시드 유사체
WO2019169324A1 (en) * 2018-03-02 2019-09-06 January Therapeutics, Inc. Nanoparticle compositions
EP4454650A4 (de) * 2021-12-22 2025-10-22 Cj Cheiljedang Corp Antivirale zusammensetzung mit von nukleinsäure abgeleiteten nukleosidanalogen und pharmazeutisch unbedenkliches salz davon

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002963A (en) * 1975-05-29 1977-01-11 North Electric Company Converter circuit and method having fast responding current balance and limiting
IT1202370B (it) * 1976-07-12 1989-02-09 Hoffmann La Roche Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti
US4849411A (en) * 1982-11-09 1989-07-18 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
GB2177914B (en) * 1985-06-04 1989-10-25 Chugai Pharmaceutical Co Ltd A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
US4786726A (en) * 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
US4962194A (en) * 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
EP0339075B1 (de) * 1987-10-28 1993-08-18 Pro-Neuron, Inc. Acylatiertes uridin und cytidin und deren verwendungen
EP0355131B1 (de) * 1987-10-28 1996-09-04 Pro-Neuron, Inc. Acyl deoxyribonukleosid-derivate und deren verwendungen
ZA892928B (en) * 1988-04-25 1991-01-30 Pro Neuron Inc Pharmaceutical compositions containing deoxyribonucleosides for wound healing
ATE111157T1 (de) * 1988-04-29 1994-09-15 Genetics Inst Lagerungsstabile zusammensetzungen von homogenem dimerem m-csf.

Also Published As

Publication number Publication date
JP3393645B2 (ja) 2003-04-07
IL100874A (en) 1996-01-19
AU663309C (en) 2002-08-08
EP0570519A4 (en) 1996-02-21
EP0570519B1 (de) 1999-05-06
CA2444071C (en) 2008-10-07
CA2100655C (en) 2004-02-03
JPH06511473A (ja) 1994-12-22
DE69229108T2 (de) 1999-09-23
CA2444071A1 (en) 1992-08-20
CA2100655A1 (en) 1992-08-09
JP2001270896A (ja) 2001-10-02
ZA92914B (en) 1993-08-09
JP2003119152A (ja) 2003-04-23
DE69229108D1 (de) 1999-06-10
HK1003425A1 (en) 1998-10-30
AU1417792A (en) 1992-09-07
JP4067926B2 (ja) 2008-03-26
RU2158269C2 (ru) 2000-10-27
JP3885006B2 (ja) 2007-02-21
JP3996352B2 (ja) 2007-10-24
KR100418483B1 (ko) 2004-02-11
IL100874A0 (en) 1992-11-15
JP2003064092A (ja) 2003-03-05
JP2003160585A (ja) 2003-06-03
AU663309B2 (en) 1995-10-05
EP0570519A1 (de) 1993-11-24
KR100263943B1 (ko) 2000-08-16
WO1992013561A1 (en) 1992-08-20
JP3760149B2 (ja) 2006-03-29
JP2006096772A (ja) 2006-04-13

Similar Documents

Publication Publication Date Title
DE69229108D1 (de) Oxypurin-nukleoside und seine artverwandten, und acylderivate davon, zur verbesserung der hämatopoese
EA200001146A1 (ru) Производные изотиазола, применимые в качестве противораковых агентов
JPS5564571A (en) Novel 1*44dihydropyridine compound having substituted ester group
DE69133397D1 (de) Benzoylderivate
MX9203050A (es) Compuestos de analogos de triptamina.
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
PT98905A (pt) Processo para a preparacao de mono-hidrato de furoato de mometasona,e de composicoes farmaceuticas que o contem
FI831230L (fi) N-glykosylerade karboxylsyraamidderivat, foerfarande foer deras framstaellning samt deras anvaendnifoer att paoverka kroppens eget foersvar
DK1005271T3 (da) Synergistisk biocidsammensætning
RU93053905A (ru) Оксипуриновые нуклеозиды и родственные им соединения, а также их ацильные производные для улучшения гемопоэза, фармацевтическая композиция и способ лечения и/или профилактики
IL70585A0 (en) Substituted 4-aminomethylene-chromans and-chromenes,their preparation and pharmaceutical compositions containing them
PT911331E (pt) Compostos de dibenzoxazepina substituidos composicoes farmaceuticas e metodos de utilizacao
ES2191659T3 (es) Derivados heterociclicos substituidos utiles como inhibidores de la agregacion plaquetaria.
FI945975A0 (fi) Haarautuneella aminoryhmällä substituoituja tiatsoleja, menetelmiä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
ATE180781T1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
NO970631L (no) Fremgangsmåter for behandling av sepsis eller betennelsessykdommer med oxypurin-nukleosider
SE8202380L (sv) Analgetisk komposition
IE810391L (en) Trihydroxypiperidine derivatives.
GR71207B (de)
DK164191C (da) Fungicid og fremgangsmaader til dets fremstilling og til dets anvendelse til bekaempelse af svampe
ES2150461T3 (es) Derivados de amidinofenilalanina, proceso para su preparacion, su empleo y agentes que los contienen como anticoagulantes.
SE8303700L (sv) Terapeutisk komposition
MX9206729A (es) Composicion de alimento para peces.
DE69212947D1 (de) Conalbumin und seine Derivate enthaltende Eisenkomplexe
BR8400127A (pt) Composicao para o combate de crescimento indesejado de plantas,processo para a obtencao de 3,4-di-(metilamino)-6-terc.-butil-4,5-dihidro-1,2,4-triazin-5-ona,processo para a obtencao de uma composicao utilizacao e processo para o combate de ervas daninhas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
REN Ceased due to non-payment of the annual fee